Prospective intra/inter-observer evaluation of pre-brachytherapy cervical cancer tumor width measured in TRUS and MR imaging.
Adenocarcinoma
/ pathology
Adenocarcinoma, Clear Cell
/ pathology
Adult
Aged
Aged, 80 and over
Brachytherapy
Carcinoma, Squamous Cell
/ pathology
Female
Humans
Magnetic Resonance Imaging
/ methods
Middle Aged
Observer Variation
Prognosis
Prospective Studies
Ultrasonography
/ methods
Uterine Cervical Neoplasms
/ pathology
Young Adult
3D brachytherapy
Cervical Cancer
Image guided brachytherapy
Magnetic resonance
TRUS
Ultrasound
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
04 Oct 2019
04 Oct 2019
Historique:
received:
14
03
2019
accepted:
01
08
2019
entrez:
6
10
2019
pubmed:
6
10
2019
medline:
13
3
2020
Statut:
epublish
Résumé
Ultrasound (US) imaging has been proved as an excellent diagnostic tool in gynecology and, due to its wide availability and limited cost, is under intense investigation as base for dose adaptation in cervical cancer brachytherapy. Purpose of this work is to test inter/intra-observer uncertainties between magnetic resonance (MR) and trans-rectal ultrasound (TRUS) imaging in defining maximum tumor width before first brachytherapy (BT) application in a prospective cohort of cervical cancer patients undergoing image-guided adaptive brachytherapy (IGABT). One hundred ten consecutive cervical cancer patients treated between 2013 and 2016 were included. Before the first BT implant patients underwent MR and TRUS scan with no applicator in place. Images were independently analyzed by three examiners, blinded to the other's results. With clinical information at hand, maximum tumor width was measured on preBT TRUS and MR. Quantitative agreement analysis was undertaken. Intra-class correlation coefficient (ICC), Passing-Bablok and Bland Altman plots were used to evaluate the intra/inter-observers measurement agreement. Average difference between tumor width measured on MR (HRCTV Our results suggest that TRUS is equivalent to MR in assessing preBT tumor maximum width in cervical cancer FIGO stage I/II. In more advanced stages TRUS seems to be slightly inferior to MR although maintaining a good agreement to gold standard imaging.
Sections du résumé
BACKGROUND
BACKGROUND
Ultrasound (US) imaging has been proved as an excellent diagnostic tool in gynecology and, due to its wide availability and limited cost, is under intense investigation as base for dose adaptation in cervical cancer brachytherapy. Purpose of this work is to test inter/intra-observer uncertainties between magnetic resonance (MR) and trans-rectal ultrasound (TRUS) imaging in defining maximum tumor width before first brachytherapy (BT) application in a prospective cohort of cervical cancer patients undergoing image-guided adaptive brachytherapy (IGABT).
METHODS
METHODS
One hundred ten consecutive cervical cancer patients treated between 2013 and 2016 were included. Before the first BT implant patients underwent MR and TRUS scan with no applicator in place. Images were independently analyzed by three examiners, blinded to the other's results. With clinical information at hand, maximum tumor width was measured on preBT TRUS and MR. Quantitative agreement analysis was undertaken. Intra-class correlation coefficient (ICC), Passing-Bablok and Bland Altman plots were used to evaluate the intra/inter-observers measurement agreement.
RESULTS
RESULTS
Average difference between tumor width measured on MR (HRCTV
CONCLUSIONS
CONCLUSIONS
Our results suggest that TRUS is equivalent to MR in assessing preBT tumor maximum width in cervical cancer FIGO stage I/II. In more advanced stages TRUS seems to be slightly inferior to MR although maintaining a good agreement to gold standard imaging.
Identifiants
pubmed: 31585543
doi: 10.1186/s13014-019-1352-7
pii: 10.1186/s13014-019-1352-7
pmc: PMC6778388
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
173Références
Radiology. 1992 Oct;185(1):201-5
pubmed: 1523308
Brachytherapy. 2012 Jan-Feb;11(1):47-52
pubmed: 22265437
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Brachytherapy. 2017 Jan - Feb;16(1):85-94
pubmed: 27919654
Best Pract Res Clin Obstet Gynaecol. 2014 Jul;28(5):741-68
pubmed: 24861248
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):598-604
pubmed: 26867888
Ultrasound Obstet Gynecol. 2013 Dec;42(6):705-12
pubmed: 23495185
Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):83-90
pubmed: 16839702
Radiother Oncol. 2006 Jan;78(1):67-77
pubmed: 16403584
Radiother Oncol. 2016 Sep;120(3):447-454
pubmed: 27157510
Radiother Oncol. 2010 Aug;96(2):153-60
pubmed: 20663578
Int J Gynecol Cancer. 2008 Jul-Aug;18(4):766-72
pubmed: 17892456
Brachytherapy. 2012 Jan-Feb;11(1):33-46
pubmed: 22265436
Brachytherapy. 2016 Nov - Dec;15(6):839-844
pubmed: 27693172
Radiother Oncol. 2011 Jul;100(1):116-23
pubmed: 21821305
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):588-97
pubmed: 26867887
Radiother Oncol. 2012 Jun;103(3):305-13
pubmed: 22633469
Acta Oncol. 2013 Oct;52(7):1384-90
pubmed: 23957566
Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):307-17
pubmed: 9607346
Radiother Oncol. 2016 Sep;120(3):428-433
pubmed: 27134181
Psychol Bull. 1979 Mar;86(2):420-8
pubmed: 18839484
Radiother Oncol. 2012 Apr;103(1):113-22
pubmed: 22296748
Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):788-96
pubmed: 26530747
Strahlenther Onkol. 2009 May;185(5):282-7
pubmed: 19440666
Strahlenther Onkol. 2013 Feb;189(2):123-8
pubmed: 23255091
Radiother Oncol. 2005 Mar;74(3):235-45
pubmed: 15763303
Radiother Oncol. 2010 Feb;94(2):173-80
pubmed: 20138380
Gynecol Oncol. 2013 Mar;128(3):449-53
pubmed: 23022593
Acta Oncol. 2013 Oct;52(7):1510-9
pubmed: 23962242
Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):667-76
pubmed: 2004942
Radiother Oncol. 2016 Sep;120(3):467-472
pubmed: 26921168
Brachytherapy. 2015 Nov-Dec;14(6):910-2
pubmed: 26427957
Radiother Oncol. 2013 Apr;107(1):75-81
pubmed: 23068712
Acta Oncol. 2013 Oct;52(7):1345-52
pubmed: 23905674
J Minim Invasive Gynecol. 2017 May - Jun;24(4):609-616
pubmed: 28161495
Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):860-5
pubmed: 24462382
Brachytherapy. 2015 May-Jun;14(3):390-400
pubmed: 25620161
Curr Oncol Rep. 2015 Jun;17(6):28
pubmed: 25980344
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):491-8
pubmed: 17331668
Brachytherapy. 2016 Nov - Dec;15(6):817-824
pubmed: 27593599
Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):111-9
pubmed: 23849695
J Clin Chem Clin Biochem. 1983 Nov;21(11):709-20
pubmed: 6655447